Semaglutide Linked to 40% Fewer Asthma Attacks
Analysis based on 22 articles · First reported Sep 07, 2026 · Last updated Sep 24, 2026
The study could broaden the perceived therapeutic profile of semaglutide beyond diabetes and obesity, potentially supporting longer-term demand expectations for Novo Nordisk's GLP-1 franchise. However, because the findings are observational and researchers explicitly warn against changing prescribing guidance, any near-term revenue impact is likely limited and sentiment-driven.
A real-world study led by Professor Chloe Bloom of the National Heart & Lung Institute at Imperial College London, and presented by Dr Bohee Lee, found that semaglutide, the active ingredient in Ozempic and Wegovy, was associated with nearly 40% fewer asthma attacks and a 20% reduction in COPD flare-ups. The research was presented at the European Respiratory Society Congress in Spain — Barcelona, Spain. The team analyzed UK electronic medical records across four parallel studies, each involving 20,000 to 22,000 people who had started a GLP-1 medication or a sulfonylurea. Among the GLP-1 drugs examined, only semaglutide showed a significant association, with the strongest effect in people with asthma. Researchers cautioned that the observational findings do not prove causation and should not change prescribing guidance; clinical trials are needed. Dr Alexander Mathioudakis of the University of Manchester and the European Respiratory Society noted the study highlights metabolic health in respiratory care. Dr List of Home and Away characters introduced in 1989 of Asthma + Lung UK called the results promising, particularly for patients with obesity or diabetes.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard